Serono launches Zorbtive for short bowel syndrome

9 May 2004

Serono Inc has launched Zorbtive (somatropin for injection) for the treatment of patients with short bowel syndrome, following US Food and Drug Administration approval at the end of last year (Marketletter December 8, 2003). Approval was granted on results from a pivotal clinical trial which demonstrated that a four-week regimen of the drug, administered together with a specialized diet, significantly reduced dependence on intravenous nutrition, as measured by total volume, total calories and infusion frequency.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight